Form 4: TOI Director Sells 50,000 Shares Under 10b5-1 Plan

The Oncology Institute Director Mark L. Pacala sold 50,000 shares of common stock for $4 per share, acquired from vested RSU awards, under a pre-arranged plan.

Summary

• Mark L. Pacala, a Director of The Oncology Institute, Inc. (TOI), reported sales of common stock.
• The transactions occurred on November 18, 2025.
• A total of 50,000 shares were sold across three separate transactions (2,160, 1,210, and 46,630 shares).
• All shares were sold at a price of $4.00 per share.
• The shares sold were acquired from previously vested Restricted Stock Unit (RSU) awards.
• Following these transactions, Mr. Pacala beneficially owns 174,971 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even if pre-planned, can be perceived as a slight negative signal by the market, though the Rule 10b5-1 plan mitigates some of the negative sentiment. It's a routine insider transaction, not indicative of company performance.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-arranged sale plan rather than an immediate reaction to new information, which can mitigate negative market perception.

Negatives

• A director sold a significant number of shares (50,000 shares) at $4.00 per share, which could be interpreted by some investors as a lack of strong conviction in the near-term stock price appreciation.

Risks

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock price may not rise significantly in the near term.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but rather reports a past insider transaction.

Management Comments

• The sales represent common stock acquired from previously vested RSU awards.

Industry Context

Insider transactions, such as this director's sale, are common in the healthcare services industry, particularly when executives or directors monetize vested equity awards. The impact on the company's stock price often depends on the size of the sale relative to the insider's total holdings and the company's market capitalization, as well as the broader market sentiment towards the sector.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider transaction. There are no specific company or project results to compare to industry benchmarks.
• Insider sales are a common occurrence across all industries, often for personal financial planning or diversification, especially when conducted under a Rule 10b5-1 plan.
• Without further context on the company's performance or other insider activity, it is difficult to draw direct comparisons to specific comparable companies or projects.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially impacting short-term sentiment, although the Rule 10b5-1 plan suggests a pre-arranged, non-event-driven sale.

Next Steps

• The filing does not specify any future actions or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

The filing reports a routine insider sale by a director under a Rule 10b5-1 plan, monetizing previously vested RSU awards. While insider selling can sometimes be viewed negatively, the pre-planned nature suggests it's for personal financial management rather than a reaction to new adverse company information. This single transaction does not provide sufficient information to change a fundamental investment thesis, thus a 'hold' recommendation is appropriate, pending further company-specific news or broader market developments.

Keywords

The Oncology Institute, TOI, Insider Trading, Form 4, Stock Sale, Director, Mark L. Pacala, RSU